triple-hormone-receptor agonist retatrutide for obesity ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with or “overweight” Retatrutide Weight Loss | GLP-1,

Participants eating traditional sized meals (500 to 700 calories) experienced nausea rates of 41%

The primary endpoint was percent change in weight at week 80 with retatrutide 9 mg or 12 mg

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

doi: 10.1016/j.tice.2015.12.003 163 GebremedhnSSalilew-WondimDHoelkerMRingsFNeuhoffCTholenEet al

Larger Phase 3 studies are now underway to better define long-term efficacy and safety

SRK 439 is a monoclonal antibody which selectively binding to pro- and latent myostatin molecules